The strategic review process (potential sale/merger) is the primary catalyst. Monitor for any definitive agreement or financing announcement. The failed HLHS trial and limited cash runway increase the likelihood of a dilutive financing or distressed sale.
Drug in focus
LGVN drug pipeline →laromestrocel
▼ Bearish Named in this press release- Impact
- Phase
- Phase 2
- Time to market
- Not stated
- Next catalyst
- None dated
What to watchThe next near-term event is the AHA 2026 Scientific Sessions podium presentation of the ELPIS II secondary endpoint data (date TBD). A positive reception could provide a short-term bounce, but the primary endpoint failure already limits the HLHS regulatory path. The bigger binary is the outcome of the strategic alternatives review, a sale or partnership could unlock value, while failure to find a deal could force a dilutive financing or a wind-down. Watch for 8-K filings for any 8-K regarding a potential sale, financing or Nasdaq compliance notice.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $2.49entry
- T+1 · 20h ago −14.06%α −12.14% · $2.14
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Longeveron reported Q3 2026 net loss of $6.1M ($1.91 per share) on revenue of $0.1M, missing the consensus EPS estimate of -$1.70. The ELPIS II Phase 2b trial for HLHS failed its primary endpoint, and the company has initiated a strategic review process with Lucid Capital Markets, exploring a potential sale or merger. Cash stands at $7.2M, expected to fund operations into Q1 2027.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $6.1M, or $1.91 per share, on revenue of $0.1M
- EPS of -$1.91 missed consensus of -$1.70 (surprise -12.4%)
- Revenue declined 16% YoY to $0.1M, in line with consensus of $0.8M? (consensus $800K appears to be annualized or misaligned; actual quarterly revenue $115K)
- ELPIS II Phase 2b trial for HLHS failed primary endpoint (RVEF at Month 12)
- Company initiated strategic review, retained Lucid Capital Markets for potential sale/merger
- Cash and cash equivalents of $7.2M as of Sep 30, 2026, expected to fund operations into Q1 2027
- No conference call held due to strategic review process
- 1-for-10 reverse stock split effective August 26, 2026
Financial Impact
Net loss of $6.1M on $0.1M revenue; cash runway into Q1 2027; EPS miss of $0.21 vs consensus
Risk Factors
- ELPIS II trial failure may impair HLHS program viability and FDA path
- Cash only into Q1 2027; substantial doubt about going concern without financing or deal
- Strategic review may not result in favorable terms or any transaction
- Nasdaq continued listing risk given sub-$1M market cap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402293 |
Track record
22 reports on LGVN
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
- Nov 12, 20264d ago 8-K Bearish 7/10 No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Viewing Entry $2.49 Now $2.14 +14.06% settles Feb 11
- Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
- Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
- Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
- Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers